Abstract
Background: Glutaric aciduria type I (GA-I) is an autosomal recessive inherited metabolic disease due to a deficiency of glutaryl-CoA dehydrogenase, which if untreated results in severe neurological impairment. Combined metabolic treatment (low-lysine diet, carnitine supplementation, and emergency treatment) according to evidence-based guideline recommendations (Kölker et al 2011) has significantly reduced the manifestation of striatal injury and secondary dystonia in glutaric acidemia type I (GA-I) patients. However, development of cognitive functions in these patients has not yet been studied in detail.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
